newsfilter
← Earnings
Earnings Releases·

Denali Therapeutics — Third Quarter 2026 Earnings Summary

Denali Therapeutics reported third-quarter 2026 net product revenue of $17.8 million from AVLAYAH, its FDA-approved treatment for Hunter syndrome, which saw commercial coverage exceed 70% of U.S. commercial lives. The company recorded a net income of $70.1 million for the quarter, driven by a one-time $194.0 million gain from the sale of a Priority Review Voucher, bringing its cash, cash equivalents, and marketable securities to approximately $1.0 billion. Denali expects fourth-quarter 2026 net product revenue to range between $30.0 million and $32.0 million and anticipates submitting a Biologics License Application for its second potential product, zafinofusp alfa, in 2027.

Company
DENALI THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology